Revance Therapeutics Inc (RVNC) Receives Average Recommendation of “Buy” from Brokerages

Shares of Revance Therapeutics Inc (NASDAQ:RVNC) have been assigned a consensus rating of “Buy” from the six analysts that are covering the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $35.00.

A number of equities research analysts have weighed in on RVNC shares. Aegis reiterated a “buy” rating and set a $28.00 price target on shares of Revance Therapeutics in a research note on Thursday, January 19th. Zacks Investment Research upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 1st.

Several large investors have recently modified their holdings of RVNC. Bank of America Corp DE boosted its position in Revance Therapeutics by 29.5% in the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,651 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Revance Therapeutics during the fourth quarter worth about $174,000. Rothschild Asset Management Inc. boosted its position in Revance Therapeutics by 2.6% in the third quarter. Rothschild Asset Management Inc. now owns 10,808 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 269 shares in the last quarter. Wells Fargo & Company MN boosted its position in Revance Therapeutics by 19.1% in the third quarter. Wells Fargo & Company MN now owns 10,987 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 1,759 shares in the last quarter. Finally, American International Group Inc. boosted its position in Revance Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 834 shares in the last quarter.

Shares of Revance Therapeutics (NASDAQ:RVNC) traded up 6.46% during mid-day trading on Friday, hitting $20.60. 396,950 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $20.89 and a 200-day moving average price of $19.69. Revance Therapeutics has a 52 week low of $12.35 and a 52 week high of $24.30. The company’s market capitalization is $623.62 million.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.10. Revance Therapeutics had a negative return on equity of 37.31% and a negative net margin of 28,187.33%. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.07 million. During the same quarter in the prior year, the firm earned ($0.71) EPS. The firm’s quarterly revenue was up .0% on a year-over-year basis. On average, equities analysts anticipate that Revance Therapeutics will post ($3.68) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/19/revance-therapeutics-inc-rvnc-receives-average-recommendation-of-buy-from-brokerages.html.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

5 Day Chart for NASDAQ:RVNC

Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply